A Phase 2/3 interventional study of Taurine and Placebo in Long COVID, sponsored by University of Alberta. Recruiting at 5 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-18.
Sponsored by University of Alberta · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies in Post-Acute COVID-19 Syndrome with a site in Canada — 14 open to participants now, 17 under way, 3 of them phase 3. Post-Acute COVID-19 Syndrome · Canada.
Among the 40 studies in Post-Acute COVID-19 Syndrome with a site in Canada, this one is the 4th largest by planned enrollment of the 33 interventional ones that give a count, is one of 7 that started in 2025, is one of 3 in phase 2/3, reaches primary completion later than 12 of the 16 other live ones, and was the 30th registered.
605 studies on the registry are indexed under Post-Acute COVID-19 Syndrome; 201 are open to participants now.
Browse Post-Acute COVID-19 Syndrome studies →14 of the 40 studies in Post-Acute COVID-19 Syndrome with a site in Canada are open now. Recruiting first, the newest first:
York University · Sites in Canada
Ages 18–65
ParagonClinicals Inc. · Sites in Canada
Ages 19+
Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec · Sites in Canada
Ages 18+
University Health Network, Toronto · Sites in Canada
Ages 18+
Douglas D. Fraser · Sites in Canada, United States, Brazil and 4 more countries
Ages 18–65
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 145 Post-Acute COVID-19 Syndrome studies recruiting now, 70 (48%) set no upper age limit and 53 (37%) stop at 75 or younger; 15 take children under 18; 39 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 6 · Phase 3 5 · Phase 4 1
First in 2021; this study’s year is marked. 7 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 300 is above the median of 60 across 417 interventional studies indexed under Post-Acute COVID-19 Syndrome.
Median enrollment 82 across the 33 interventional studies, 120 across the 7 observational. Of the 20 that completed or were terminated, 2 (10%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 40 have an industry lead sponsor. The 10 most frequent:
University of Alberta is the lead sponsor of 824 studies on the registry; 171 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.
University of Alberta has 5 studies filed under Post-Acute COVID-19 Syndrome — fewer than ten, so there is no comparison to draw.
5 of the studies in Post-Acute COVID-19 Syndrome with a site in Canada that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06928272Phase 3Douglas D. FraserLong Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug Study | 2026-12 |
| NCT07374562Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-QuébecStellate Ganglion Block for Long COVID Symptoms: A Randomized Controlled Trial | 2027-02 |
| NCT04736732Emilia Falcone, MDInstitut de Recherche Cliniques de Montreal (IRCM) Post-COVID-19 (IPCO) Research Clinic | 2027-05-04 |
| NCT07312409York UniversityDoes Taurine Supplementation Improve Vascular Function and Orthostatic Responses in Long COVID? | 2027-06-30 |
| NCT06082518Sunnybrook Health Sciences CentreImproving Post COVID-19 Syndrome With Hyperbaric Oxygen Treatments | 2027-07 |
Add all 5 to your calendar (.ics) → With an account.
Among the 40 studies in Post-Acute COVID-19 Syndrome with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The COVID-19 pandemic has swept across the globe, affecting millions of individuals with varying degrees of severity. While many individuals recover from the acute phase of the infection, a significant proportion continue to experience persistent and debilitating symptoms long after the initial SARS-CoV-2 infection. This condition, known as Long COVID (LC) or sometimes referred to as Post-COVID Condition (PCC) or post-acute sequelae of COVID-19, has emerged as a complex multisystemic condition and challenging health issue, affecting approximately 10% of COVID-19 patients. Various symptoms characterize LC, including fatigue, sleep disturbances, cognitive impairment, and mood disturbances. Some of the symptoms are shared with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) - a condition marked by debilitating fatigue and a host of other symptoms without precise biomarkers or objective tests for diagnosis. Effective LC treatments remain elusive and LC patients continue to grapple with persistent symptoms that significantly impact their quality of life. Given the lack of effective treatments, it is imperative to explore novel therapeutic approaches that may alleviate the suffering of this patient population.
Purpose: The overall trial objectives are to evaluate the efficacy and safety of taurine supplementation in treating and managing prolonged symptoms related to LC, focusing on neurocognitive-associated symptoms and fatigue.
Hypothesis: Increasing taurine levels in the body through treatment with taurine supplements will have a beneficial effect on Long COVID symptoms particularly neurocognitive-associated symptoms and fatigue.
Justification: Previous studies have suggested a correlation between low plasma taurine levels and symptoms associated with Long COVID. Reduced plasma taurine levels have also been observed in patients with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). The decreasing trajectory of taurine levels observed in long COVID could partly explain the fatigue, as taurine plays multiple roles in skeletal muscle function, the central nervous system, and energy metabolism. Furthermore, in various clinical and preclinical studies, including antioxidant, anti-aging, cytoprotective, and cardioprotective effects, taurine has demonstrated various therapeutic activities. Taurine also has a role in neuromodulation and the treatment of other central nervous system disorders, including depression. These findings suggest that taurine may be important in addressing the persistent symptoms and adverse outcomes in LC patients.
Given the robust association between taurine levels and symptoms and adverse outcomes of LC and the safety profile, there is a strong biological and clinical rationale for investigating taurine supplementation. There is a lack of effective treatments for LC, and exploring taurine supplementation as a novel therapeutic approach is justified and holds the potential to significantly improve the lives of affected individuals with an excellent safety profile.
Objectives: The overall trial objectives are to evaluate the efficacy and safety of taurine supplementation in treating and managing prolonged symptoms related to LC, focusing on neurocognitive-associated symptoms and fatigue.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants randomized to the Taurine arm will receive two 675 mg taurine capsules twice daily for 12 weeks.
Drug: Taurine
Participants randomized to the Placebo arm will receive two placebo capsules twice daily for 12 weeks. The placebo capsules will be visually identical to the taurine capsules.
Drug: Placebo
Taurine is a naturally occurring amino sulfonic acid commonly found in the body. It is marketed as a natural health product/supplement and plays an important role in the body.
The placebo capsule is visually identical to the taurine capsule.
Mean change in Modified Fatigue Impact Scale (MFIS) from baseline to three months
This study will target detection of a change in the MFIS from baseline to three months
Time frame: Three months
Mean change in the ratio of the Trail-Making Tests A & B in the TestMyBrain cognitive testing battery from baseline to three months.
This test will target detection of a change in the ratio of the Trail-Making Tests A \& B from baseline to three months
Time frame: Three months
Core Outcome Set - Symptoms
Tracking of symptom trajectory from baseline to three months
Time frame: Three months
Cardiovascular function
Mean change in results of 6-minute walking test, to include symptoms and conditions
Time frame: Three months
Respiratory function
Mean change in results of 6-minute walking test, to include symptoms and conditions
Time frame: Three months
Cognitive Function
Measurement of mean change in cognition using the TestMyBrain assessment tool.
Time frame: Three months
Memory
Measurement of mean change in memory using the TestMyBrain assessment tool.
Time frame: Three months
Concentration
Measurement of mean change in concentration using the TestMyBrain assessment tool.
Time frame: Three months
Conceptual Thinking
Measurement of mean change in conceptual thinking using the TestMyBrain assessment tool.
Time frame: Three months
Social Functioning
Measurement of mean change in social functioning using the TestMyBrain assessment tool.
Time frame: Three months
Mental Health Status - PHQ-9
Measurement of mean change in mental health status using the Patient Health Questionnaire (PHQ-9).
Time frame: Three months
Mental Health Status - GAD-7
Measurement of mean change in mental health status using the General Anxiety Disorder Questionnaire (GAD-7).
Time frame: Three months
Post-Exertional Malaise (PEM) Symptoms
Measurement of changes in onset and triggers of PEM, symptoms, duration and recovery using the Post-Exertional Malaise questionnaire, adapted from De Paul's Symptom Questionnaire (PEM-DSQ).
Time frame: Three months
Post-COVID-19 Functional Status (PCFS) Scale
Measurement of changes in post-COVID functional status using the Post-COVID-19 Functional Status (PCFS) Scale.
Time frame: Three months
Reintegration to Normal Living Index (RNLI)
Measurement of changes in reintegration to normal social activities using the Reintegration to Normal Living Index (RNLI) assessment tool.
Time frame: Three months
Health Related Quality of Life - SF-36 (v.1)
Measurement of change in quality of life using the Quality of Life - SF-36 (v.1) assessment tool.
Time frame: Three months
Started Nov 2025 (actual). Primary completion is estimated for Feb 2028, 27 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Taurine
Post-Acute COVID-19 Syndrome →